IL33 and gastric cancer: Such as IL‐33 can be used as an early predictor of the efficacy of cetuximab in the treatment of colorectal cancer and the reduction of the toxicity of platinum‐based chemotherapy drugs to gastric cancer cells [91, 92, 93].